Combining microchip engineering techniques with cutting-edge gene profiling, scientists at Columbia University have developed a new way to study drug responses in living slices of human brain tumor cells. The system, using a type of chip called a microfluidic device, has already revealed new details about how these aggressive tumors resist chemotherapy drugs and could help researchers develop more effective treatments.
The work grew from earlier efforts to study glioblastoma tumors removed from patients during surgery. “These samples that we’re getting from our colleagues who resect these tumors clinically, they’re alive, and we can actually do experiments directly on those surgical samples,” says Peter Sims, Ph.D., associate professor of systems biology at Columbia and senior author on the new study, which appears in the journal Lab on a Chip.









